Oncomine Dx Express Test
Life Technologies Corporation · Decision date Aug 7, 2025
What did the FDA decide?
FDA records P240040/S001 as a supplement to PMA P240040, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 7, 2025.
FDA approval order statement
approval for manufacturing process improvements
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Pathology
- Decision date
- Aug 7, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P240040/S001
- Regulatory pathway
- PMA supplement
- Applicant
- Life Technologies Corporation
- Product code
- PQP
- Decision code
- OK30
- Decision date
- Aug 7, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.
- Applicant
- Life Technologies Corporation
- Product code
- PQP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240040. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240040 · Original PMA
Oncomine Dx Express Test
P240040/S001 received
Application receipt date recorded by FDA.
P240040/S001 · FDA decision
30-Day Notice
P240040/S002 · Related supplement
Oncomine Dx Express Test
P240040/S003 · Related supplement
Oncomine Dx Express Test
P240040/S006 · Related supplement
Oncomine Dx Express Test
P240040/S005 · Related supplement
Oncomine Dx Express Test
P240040/S008 · Related supplement
Oncomine Dx Express Test
Timeline entries are records held by MedtechLedger for P240040. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240040
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Oncomine Dx Express TestP240040 | Life Technologies Corporation | PMA approval | Jul 2, 2025 | FDA |
Oncomine Dx Express TestP240040/S002 | Life Technologies Corporation | PMA supplement | Oct 15, 2025 | FDA |
Oncomine Dx Express TestP240040/S003 | Life Technologies Corporation | PMA supplement | Oct 22, 2025 | FDA |
Oncomine Dx Express TestP240040/S006 | Life Technologies Corporation | PMA supplement | Jun 8, 2026 | FDA |
Oncomine Dx Express TestP240040/S005 | Life Technologies Corporation | PMA supplement | Sep 9, 2026 | FDA |
Oncomine Dx Express TestP240040/S008 | Life Technologies Corporation | PMA supplement | Nov 4, 2026 | FDA |
Explore the linked device profile
Other records with product code PQP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
xT CDxP210011/S006 | Tempus AI, Inc. | PMA supplement | Oct 23, 2026 | FDA |
MI Cancer SeekP240010/S007 | Caris Life Sciences | PMA supplement | Oct 16, 2026 | FDA |
FoundationOne Liquid CDx (F1LCDx)P190032/S032 | Foundation Medicine, Inc. | PMA supplement | Sep 18, 2026 | FDA |
Guardant360 CDxP200010/S029 | Guardant Health, Inc. | PMA supplement | Sep 18, 2026 | FDA |
FoundationOne CDxP170019/S069 | Foundation Medicine, Inc. | PMA supplement | Sep 16, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Life Technologies Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 7335 Executive Way, Frederick, MD, 21704
Sources and methodology
- Original FDA record: P240040/S001
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




